Article
Chemistry, Multidisciplinary
Yao Chen, Dong Zhao, Feng Xiao, Xuanyu Li, Jia'an Li, Zhenwei Su, Xingyu Jiang
Summary: In this study, a microfluidic chip was used to sequentially assemble multi-component nanoparticles, including therapeutic drugs and siRNA, with high encapsulation efficiencies and efficient tumor treatment effects.
ADVANCED MATERIALS
(2023)
Article
Biochemistry & Molecular Biology
Wei-Hsiang Hsu, Chien-Liang Ku, You-Ren Lai, Steven S. -S. Wang, Shiu-Huey Chou, Ta-Hsien Lin
Summary: This study aimed to develop DOXO-coupled glycated BSA nanoparticles and improve their targeting capability towards GLUT5 transporters over-expressed on breast cancer cells. The synthesized nanoparticles had a spherical shape with a hydrodynamic diameter of approximately 60.74 nm and a zeta-potential of approximately -42.20 mV. Furthermore, the DOXO-coupled glycated BSA nanoparticles exhibited cytotoxicity towards both MCF-7 and MDA-MB-231 cells. Overall, this research demonstrates the potential of drug-coupled glycated BSA nanoparticles as a targeted drug delivery platform for breast cancer therapy. Rating: 9/10.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
Article
Engineering, Biomedical
Chenghua Song, Jia Zhang, Ruichao Wen, Qingshan Li, Jiaxuan Zhou, Xiaoli Liu, Zheng Wu, Yi Lv, Rongqian Wu
Summary: A pH-triggered drug-eluting nanoparticle was developed for simultaneous delivery of Tim-3 siRNA and sorafenib to hepatocellular carcinoma (HCC), enhancing their anti-tumor efficacy.
MATERIALS TODAY BIO
(2022)
Article
Biochemistry & Molecular Biology
Kaushik Kuche, Vivek Yadav, M. Dharshini, Rohan Ghadi, Dasharath Chaudhari, Tushar Date, Sanyog Jain
Summary: This study investigates the synergistic effect of sorafenib and simvastatin in triggering ferroptosis for cancer therapy. The researchers developed bovine serum albumin nanoparticles loaded with both drugs and observed a significant reduction in tumor volume in in-vivo experiments. The study highlights the potential of this drug delivery system for inducing ferroptosis and improving therapeutic efficacy.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
Article
Pharmacology & Pharmacy
Ladan Dayani, Mahla Dehghani, Mahmoud Aghaei, Somayeh Taymouri, Azade Taheri
Summary: This study developed sorafenib-loaded albumin lipid nanoparticles (ALNs) for targeted drug delivery in hepatocellular carcinoma (HCC). The ALNs, consisting of medium-chain triglycerides and lactobionic acid-human serum albumin conjugate (LA-HSA conjugate), showed enhanced cytotoxicity and cellular uptake in HepG2 cells compared to untargeted ALNs. Overall, the targeted ALNs can improve the therapeutic efficacy of sorafenib in HCC.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2022)
Review
Cell Biology
Sisi Yang, Chengwei Cai, Huanqiu Wang, Xueqing Ma, Anwen Shao, Jifang Sheng, Chengbo Yu
Summary: Hepatocellular carcinoma (HCC) is a common malignant tumor worldwide, and traditional antitumor drugs have limitations. The application of nanotechnology plays a significant role in improving drug delivery and selective accumulation.
CELL COMMUNICATION AND SIGNALING
(2022)
Article
Chemistry, Physical
Jingyi Zhang, Xianjun Fu, Changling Yan, Gongke Wang
Summary: This study investigated the morphology-dependent interaction between silver nanoparticles (AgNPs) and proteins. The results showed that the particle size, shape, and dispersion of AgNPs significantly influenced the interaction with proteins. Protein coronas were formed on silver nanospheres and nanorods, leading to slightly enlarged outer sizes. In the presence of proteins, silver nanotriangles gradually transformed into nanodisks. These results indicate that the formation of a protein corona and the aggregation behaviors of AgNPs are markedly determined by their inherent morphologies.
Article
Oncology
Gong Zhang, Yufeng Wang, Bryan C. Fuchs, Wei Guo, David L. Drum, Derek J. Erstad, Baomin Shi, Albert B. DeLeo, Hui Zheng, Lei Cai, Liyuan Zhang, Kenneth K. Tanabe, Xinhui Wang
Summary: The combination of DSF/Cu and sorafenib can effectively treat HCC by targeting HCSCs both in vitro and in vivo. DSF/Cu enhances the sensitivity of HCC cells to sorafenib, inhibits proliferation of HCC cells, and decreases the stemness of HCC cells.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Linlin Li, Yifang Zou, Lingzhi Wang, Leilei Yang, Yutong Li, Anqi Liao, Zheng Chen, Zhuo Yu, Jianfeng Guo, Shulan Han
Summary: This study confirmed the potential of scutellarin for inducing immunogenic cell death in hepatocellular carcinoma cells. To enable its in vivo application, a targeted nanocarrier was developed. The nanocarrier effectively delivered scutellarin to the tumor site and reversed the immune suppressive tumor microenvironment, resulting in improved therapeutic efficacy and increased survival in a mouse model of hepatocellular carcinoma, without causing toxicity.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Pharmacology & Pharmacy
Ya-Nan Li, Xiaoju Shi, Dandan Sun, Shulan Han, Yifang Zou, Lingzhi Wang, Leilei Yang, Yutong Li, Ying Shi, Jianfeng Guo, Caitriona M. O'Driscoll
Summary: In this study, the potential of melarsoprol (MEL) for hepatocellular carcinoma (HCC) therapy was investigated for the first time using in vitro and in vivo experimental approaches. A folate-targeted polyethylene glycol-modified amphiphilic cyclodextrin nanoparticle was developed for safe, efficient and specific delivery of MEL. The targeted nanoformulation achieved cell-specific uptake, cytotoxicity, apoptosis and migration inhibition in HCC cells, and significantly prolonged the survival of mice with orthotopic tumor without causing toxicity.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Biochemistry & Molecular Biology
Menghan Wang, Xing Ma, Guoyu Wang, Yanan Song, Miao Zhang, Zhongchao Mai, Borong Zhou, Ying Ye, Wei Xia
Summary: This study found that UBR5 acts as an oncogene in HCC tissues and its expression can be inhibited by ECH. By delivering ECH to HepG2 cells through a nanoparticle-based drug delivery system, the sensitivity of HCC cells to ECH can be improved, promoting cell apoptosis and inhibiting glycolysis. In vivo experiments confirmed that this delivery system enhances the antitumor effects of ECH on HCC cells.
CELLULAR & MOLECULAR BIOLOGY LETTERS
(2022)
Article
Cell Biology
Lingxi Chen, Liangbo Sun, Xufang Dai, Tao Li, Xiaojing Yan, Yueting Zhang, Hanxi Xiao, Xiaodong Shen, Gang Huang, Wei Xiang, Yan Zhang, Dehong Tan, Shiming Yang, Yongzhan Nie, Xuequan Huang, Jiqin Lian, Fengtian He
Summary: Research revealed that long non-coding RNA CRNDE induces autophagy in HCC cells by upregulating ATG4B, leading to increased resistance to sorafenib. Furthermore, silencing CRNDE can enhance the sensitivity of HCC cells to sorafenib.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Shengjun Xu, Sunbin Ling, Qiaonan Shan, Qianwei Ye, Qifan Zhan, Guangjiang Jiang, Jianyong Zhuo, Binhua Pan, Xue Wen, Tingting Feng, Haohao Lu, Xuyong Wei, Haiyang Xie, Shusen Zheng, Jiajia Xiang, Youqing Shen, Xiao Xu
Summary: Resistance to sorafenib in hepatocellular carcinoma is closely linked to cancer stemness, with the lack of effective methods to reverse this stemness being a major obstacle in current HCC therapeutics. The development of Gal-SLPs, which target HCC and co-deliver sorafenib and shUSP22, shows promising results in suppressing USP22 expression, inhibiting multidrug resistance, and efficiently inhibiting HCC cell viability and proliferation. In vivo studies using a sorafenib-insensitive patient-derived xenograft model demonstrate potent antitumor effects and biosafety of Gal-SLPs, suggesting their potential in clinical HCC treatment.
Article
Engineering, Biomedical
Yu Xia, Guoyi Tang, Yi Chen, Changbing Wang, Min Guo, Tiantian Xu, Mingqi Zhao, Yongjian Zhou
Summary: RNA interference (RNAi) is a promising method for treating malignant tumors, and in this study, RGDfC-SeNPs were successfully synthesized as a tumor-targeted carrier for delivering siSox2 to HepG2 liver cancer cells. The results showed that RGDfC-Se@siSox2 effectively silenced Sox2, inhibited tumor cell proliferation, migration, and invasion, induced apoptosis through reactive oxygen species production and mitochondrial membrane potential disruption, and significantly inhibited tumor growth in mice bearing HepG2 tumors. These findings suggest that RGDfC-SeNPs could be a valuable gene carrier for specific gene-targeted therapy in HCC.
BIOACTIVE MATERIALS
(2021)
Article
Biochemistry & Molecular Biology
Mimansa, Manu Jamwal, Reena Das, Asifkhan Shanavas
Summary: This study reports drug nanocrystals stabilized with host-specific serum proteins, providing high loading capacity. Human serum derived curcumin nanoparticles (Cur-NanoSera) demonstrated superior in vitro anticancer efficiency compared to free drugs and exhibited good hemocompatibility. The preadsorbed protein coating prevented further protein corona formation, even after repeated serum exposures. Acute and subacute toxicity evaluations in mice showed no prominent inflammatory response or organ damage. Passive accumulation of Cur-NanoSera in a breast tumor model significantly suppressed tumor growth and controlled splenomegaly associated with tumor burden.
